A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients are eligible if they have measurable disease per RECIST v1.1 3. 2) Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor DNA as determined by molecular testing. 3) Participants must have a histological or a cytologically proven diagnosis of locally advanced, unresectable and/or metastatic cancer.

You may not be eligible for this study if the following are true:

  • 1) Disease suitable for local therapy administered with curative intent. 2) Have an active fungal, bacterial, and/or active untreated viral infection, including HIV orviral (A, B, or C) hepatitis (screening is not required). 3) The patient has a serious pre-existing medical condition(s) that, in the judgment of theInvestigator, would preclude participation in this study, including ILD, severe dyspnea atrest, or requiring oxygen therapy.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.